☆ 4.7 Letter

Sotrovimab to prevent severe COVID-19 in high-risk patients infected with Omicron BA.2

JOURNAL OF INFECTION (2022)

期刊

JOURNAL OF INFECTION

卷 85, 期 4, 页码 E104-E108

出版社

W B SAUNDERS CO LTD

DOI: 10.1016/j.jinf.2022.06.033

关键词

-

类别

Infectious Diseases

资金

ANRSvertical barMIE
Ministere des Solidarites et de la Sante
Ministere de l'Enseignement Superieur, de la Recherche et de l'Innovation

向作者/读者索取更多资源

Protocol

Reagent

作者

我是这篇论文的作者

点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7

评分不足

次要评分

新颖性

-

重要性

-

科学严谨性

-

评价这篇论文

推荐

Article Infectious Diseases

Time to negative PCR conversion amongst high-risk patients with mild-to-moderate Omicron BA.1 and BA.2 COVID-19 treated with sotrovimab or nirmatrelvir

Guillaume Martin-Blondel, Anne-Genevieve Marcelin, Cathia Soulie, Sofia Kaisaridi, Clovis Lusivika-Nzinga, Karen Zafilaza, Celine Dorival, Laura Nailler, Anais Boston, Anne-Marie Ronchetti, Clea Melenotte, Andre Cabie, Christophe Choquet, Albert Trinh-Duc, Karine Lacombe, Geraldine Gaube, Francois Coustilleres, Valerie Pourcher, Jean-Philippe Martellosio, Nathan Peiffer-Smadja, Marie Chauveau, Pierre Housset, Lionel Piroth, Mathilde Devaux, Gilles Pialoux, Aurelie Martin, Vincent Dubee, Jerome Frey, Audrey Le Bot, Charles Cazanave, Philippe Petua, Roland Liblau, Fabrice Carrat, Youri Yordanov

Summary: This study compared the clinical and virological outcomes in Omicron BA.1 and BA.2-infected patients who received sotrovimab and nirmatrelvir for the prevention of severe COVID-19. The results showed that early administration of nirmatrelvir was associated with faster viral clearance compared to sotrovimab, which may contribute to reducing transmission and preventing viral resistance.

CLINICAL MICROBIOLOGY AND INFECTION (2023)

添加到收藏夹

Article Multidisciplinary Sciences

Anatomy of Omicron BA.1 and BA.2 neutralizing antibodies in COVID-19 mRNA vaccinees

Emanuele Andreano, Ida Paciello, Silvia Marchese, Lorena Donnici, Giulio Pierleoni, Giulia Piccini, Noemi Manganaro, Elisa Pantano, Valentina Abbiento, Piero Pileri, Linda Benincasa, Ginevra Giglioli, Margherita Leonardi, Piet Maes, Concetta De Santi, Claudia Sala, Emanuele Montomoli, Raffaele De Francesco, Rino Rappuoli

Summary: In this study, Andreano and Paciello et al. provide insights into the functional and genetic characteristics of the Omicron BA.1 and BA.2 cross-protective antibody response. Their findings reveal that SARS-CoV-2 vaccines can induce neutralizing antibodies that cross-neutralize the Omicron variants and SARS-CoV-1 virus.

NATURE COMMUNICATIONS (2022)

添加到收藏夹

Article Infectious Diseases

Change in effectiveness of sotrovimab for preventing hospitalization and mortality for at-risk COVID-19 outpatients during an Omicron BA.1 and BA.1.1-predominant phase

Neil R. Aggarwal, Laurel E. Beaty, Tellen D. Bennett, Nichole E. Carlson, David A. Mayer, Kyle C. Molina, Jennifer L. Peers, Seth Russell, Matthew K. Wynia, Adit A. Ginde

Summary: The study aimed to determine the effectiveness of Sotrovimab against Omicron variant infection. The observational cohort study found that Sotrovimab was not associated with reduced 28-day hospitalization or mortality among COVID-19 patients.

INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES (2023)

添加到收藏夹

Article Immunology

Rapid Selection of Sotrovimab Escape Variants in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Omicron-Infected Immunocompromised Patients

Smaranda Gliga, Nadine Luebke, Alexander Killer, Henning Gruell, Andreas Walker, Alexander T. Dilthey, Alexander Thielen, Carolin Lohr, Charlotte Flasshove, Sarah Krieg, Joanna Ventura Pereira, Tobias Paul Seraphin, Alex Zaufel, Martin Daeumer, Hans-Martin Orth, Torsten Feldt, Johannes G. Bode, Florian Klein, Joerg Timm, Tom Luedde, Bjoern-Erik Ole Jensen

Summary: Immunocompromised patients infected with Omicron variants experience prolonged viral shedding and the emergence of escape mutations after treatment with sotrovimab. Combination therapy with remdesivir significantly reduces the occurrence of escape variants.

CLINICAL INFECTIOUS DISEASES (2023)

添加到收藏夹

Article Immunology

Serial infection with SARS-CoV-2 Omicron BA.1 and BA.2 following three-dose COVID-19 vaccination

Hope R. R. Lapointe, Francis Mwimanzi, Peter K. K. Cheung, Yurou Sang, Fatima Yaseen, Rebecca Kalikawe, Sneha Datwani, Rachel Waterworth, Gisele Umviligihozo, Siobhan Ennis, Landon Young, Winnie Dong, Don Kirkby, Laura Burns, Victor Leung, Daniel T. T. Holmes, Mari L. L. DeMarco, Janet Simons, Nancy Matic, Julio S. G. Montaner, Chanson J. J. Brumme, Natalie Prystajecky, Masahiro Niikura, Christopher F. F. Lowe, Marc G. G. Romney, Mark A. A. Brockman, Zabrina L. L. Brumme

Summary: This study assessed the immune response in an individual who experienced consecutive infections with Omicron BA.1 and BA.2 variants. The results showed that while the average immune response after the third vaccine dose was effective against BA.1 infection, even strong hybrid immunity failed to prevent BA.2 infection. This highlights the importance of maintaining additional protective measures in the face of the immune-evasive Omicron variant, despite the protective effects of vaccines against severe disease.

FRONTIERS IN IMMUNOLOGY (2022)

添加到收藏夹

Article Pharmacology & Pharmacy

Different efficacies of neutralizing antibodies and antiviral drugs on SARS-CoV-2 Omicron subvariants, BA.1 and BA.2

Hirofumi Ohashi, Takayuki Hishiki, Daisuke Akazawa, Kwang Su Kim, Joohyeon Woo, Kaho Shionoya, Kana Tsuchimoto, Shoya Iwanami, Saya Moriyama, Hitomi Kinoshita, Souichi Yamada, Yudai Kuroda, Tsukasa Yamamoto, Noriko Kishida, Shinji Watanabe, Hideki Hasegawa, Tadaki Suzuki, Ken Maeda, Shuetsu Fukushi, Yoshimasa Takahashi, Shingo Iwami, Koichi Watashi

Summary: The study quantified the intrinsic sensitivity of SARS-CoV-2 Omicron subvariants BA.2 and BA.1 to neutralizing antibodies and antiviral drugs compared with other variants. Results showed diverse sensitivities of these variants to antibodies and differences in drug responses.

ANTIVIRAL RESEARCH (2022)

添加到收藏夹

Article Immunology

The derived neutrophil to lymphocyte ratio can be the predictor of prognosis for COVID-19 Omicron BA.2 infected patients

Weiji Qiu, Qiqing Shi, Fang Chen, Qian Wu, Xiya Yu, Lize Xiong

Summary: This study analyzed inflammatory indicators in COVID-19 Omicron BA.2 infected patients and found that the derived neutrophil to lymphocyte ratio (dNLR) was the best predictor of survival.

FRONTIERS IN IMMUNOLOGY (2022)

添加到收藏夹

Article Immunology

Immune responses in COVID-19 patients during breakthrough infection with SARS-CoV-2 variants Delta, Omicron-BA.1 and Omicron-BA.5

Maren Bormann, Leonie Brochhagen, Mira Alt, Mona Otte, Laura Thuemmler, Lukas van de Sand, Ivana Kraiselburd, Alexander Thomas, Jule Gosch, Peer Brass, Sandra Ciesek, Marek Widera, Sebastian Dolff, Ulf Dittmer, Oliver Witzke, Folker Meyer, Monika Lindemann, Andreas Schoenfeld, Hana Rohn, Adalbert Krawczyk

Summary: This study investigated the cellular and humoral immune responses of hospitalized COVID-19 patients during the Delta and Omicron infection waves. The results showed that the Omicron-BA.5 variant had a significant impact on neutralizing antibodies, while Delta and Omicron-BA.1 infections boosted the humoral immunity in double-vaccinated patients. Despite breakthrough infection with the BA.5 variant, these patients may still be vulnerable to reinfection with BA.5 or other newly emerging variants of concern.

FRONTIERS IN IMMUNOLOGY (2023)

添加到收藏夹

Article Multidisciplinary Sciences

Protection of COVID-19 vaccination and previous infection against Omicron BA.1, BA.2 and Delta SARS-CoV-2 infections

Stijn P. Andeweg, Brechje de Gier, Dirk Eggink, Caroline van den Ende, Noortje van Maarseveen, Lubna Ali, Boris Vlaemynck, Raf Schepers, Susan J. M. Hahne, Chantal B. E. M. Reusken, Hester E. de Melker, Susan van den Hof, Mirjam J. Knol

Summary: Protection against Omicron BA.1 and BA.2 infection is low, but booster vaccines temporarily increase protection. Previous infection, primary vaccination, and booster vaccination offer similar protection against Omicron BA.1 and BA.2 infection. Higher protection is observed in individuals with both vaccination and previous infection.

NATURE COMMUNICATIONS (2022)

添加到收藏夹

Article Infectious Diseases

Outcomes of pregnant women exposed to Sotrovimab for the treatment of COVID-19 in the BA.1 Omicron predominant era (PRESTO)

Jessica J. Tuan, Manas Sharma, Jehanzeb Kayani, Matthew W. Davis, Dayna McManus, Jeffrey E. Topal, Onyema Ogbuagu

Summary: This study reviewed clinical data of pregnant women treated with sotrovimab and found that the drug was well tolerated with good clinical outcomes. Pregnancy and neonatal complications related to sotrovimab were rare. Although the sample size was limited, the data helps to elucidate the safety and tolerability of sotrovimab in pregnant women.

BMC INFECTIOUS DISEASES (2023)

添加到收藏夹

Article Medicine, General & Internal

Effectiveness of inactivated and Ad5-nCoV COVID-19 vaccines against SARS-CoV-2 Omicron BA. 2 variant infection, severe illness, and death

Zhuoying Huang, Shuangfei Xu, Jiechen Liu, Linlin Wu, Jing Qiu, Nan Wang, Jia Ren, Zhi Li, Xiang Guo, Fangfang Tao, Jian Chen, Donglei Lu, Xiaodong Sun, Weibing Wang

Summary: This real-world study examines the effectiveness of inactivated and Ad5-nCoV COVID-19 vaccines, revealing limited protection against Omicron variants in terms of infection but high protection against severe/critical illness and death. The study emphasizes the importance of full-series vaccination and timely booster dose administration for eligible individuals.

BMC MEDICINE (2022)

添加到收藏夹

Article Immunology

Sotrovimab Resistance and Viral Persistence After Treatment of Immunocompromised Patients Infected With the Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant

Sammy Huygens, Bas Oude Munnink, Arvind Gharbharan, Marion Koopmans, Bart Rijnders

Summary: Viral evolution was studied in 47 immunocompromised patients treated with sotrovimab. Sequencing of SARS-CoV-2 after therapy was successful in 16 patients. Mutations associated with sotrovimab resistance were detected in 6 patients, and viral replication persisted after 30 days in 5 patients. Combination antibody therapy may be necessary to prevent acquired resistance in immunocompromised patients.

CLINICAL INFECTIOUS DISEASES (2023)

添加到收藏夹

Article Infectious Diseases

Real-world effectiveness of nirmatrelvir/ritonavir against COVID-19 hospitalizations and severe COVID-19 in community-dwelling elderly Singaporeans during Omicron BA.2, BA.4/5, and XBB transmission

Liang En Wee, An Ting Tay, Calvin Chiew, Barnaby Edward Young, Betty Wong, Ruth Lim, Ching Li Lee, Joyce Tan, Shawn Vasoo, David Chien Lye, Kelvin Bryan Tan

Summary: The usage of nirmatrelvir/ritonavir was found to reduce the risk of hospitalization among older community-dwelling Singaporeans during waves of Omicron transmission. However, it did not significantly reduce the risk of severe COVID-19 in a highly vaccinated population.

CLINICAL MICROBIOLOGY AND INFECTION (2023)

添加到收藏夹

Article Multidisciplinary Sciences

BA.2 and BA.5 omicron differ immunologically from both BA.1 omicron and pre-omicron variants

Annika Roessler, Antonia Netzl, Ludwig Knabl, Helena Schaefer, Samuel H. Wilks, David Bante, Barbara Falkensammer, Wegene Borena, Dorothee von Laer, Derek J. Smith, Janine Kimpel

Summary: Studies have shown that the omicron variant of SARS-CoV-2 is an immune escape variant. However, the BA.2 and BA.5 sub-variants of omicron have become dominant in many countries and replaced the BA.1 variant. Our analysis focused on whether BA.2 and BA.5 show further immune escape compared to BA.1. We found that unvaccinated individuals after a single exposure to BA.2 had limited cross-neutralizing antibodies to pre-omicron variants and BA.1.

NATURE COMMUNICATIONS (2022)

添加到收藏夹

Article Biochemistry & Molecular Biology

Original SARS-CoV-2 monovalent and Omicron BA.4/BA.5 bivalent COVID-19 mRNA vaccines: phase 2/3 trial interim results

Spyros Chalkias, Jordan L. Whatley, Frank Eder, Brandon Essink, Shishir Khetan, Paul Bradley, Adam Brosz, Nichole Mcghee, Joanne E. Tomassini, Xing Chen, Xiaoping Zhao, Andrea Sutherland, Xiaoying Shen, Bethany Girard, Darin K. Edwards, Jing Feng, Honghong Zhou, Stephen Walsh, David C. Montefiori, Lindsey R. Baden, Jacqueline M. Miller, Rituparna Das

Summary: This ongoing, open-label phase 2/3 trial compared the safety and immunogenicity of the Omicron BA.4/BA.5-containing bivalent mRNA1273.222 vaccine with the ancestral Wuhan-Hu-1 mRNA-1273 as booster doses. The bivalent vaccine showed superior neutralizing antibody responses against Omicron BA.4/BA.5 and noninferior responses against ancestral SARS-CoV-2 (D614G). The safety profile of the bivalent vaccine was similar to the ancestral vaccine.

NATURE MEDICINE (2023)

添加到收藏夹

Article Immunology

Birth Country Influences the Choice of Antiretroviral Therapy in HIV-Infected Individuals: Experience From a French HIV Centre

Romain Palich, Rachid Agher, Dimoke J. Wetshikoy, Lise Cuzin, Sophie Seang, Cathia Soulie, Roland Tubiana, Marc-Antoine Valantin, Luminita Schneider, Valerie Pourcher, Anne-Genevieve Marcelin, Lambert Assoumou, Christine Katlama

Summary: This study aims to explore the differences in antiretroviral therapy (ART) prescriptions between naive and virally suppressed HIV patients born in France and Sub-Saharan Africa. The findings suggest that the differences in ART prescriptions between these two groups cannot solely be explained by different clinical and virologic situations.

JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2023)

添加到收藏夹

Article Infectious Diseases

Time to negative PCR conversion amongst high-risk patients with mild-to-moderate Omicron BA.1 and BA.2 COVID-19 treated with sotrovimab or nirmatrelvir

Guillaume Martin-Blondel, Anne-Genevieve Marcelin, Cathia Soulie, Sofia Kaisaridi, Clovis Lusivika-Nzinga, Karen Zafilaza, Celine Dorival, Laura Nailler, Anais Boston, Anne-Marie Ronchetti, Clea Melenotte, Andre Cabie, Christophe Choquet, Albert Trinh-Duc, Karine Lacombe, Geraldine Gaube, Francois Coustilleres, Valerie Pourcher, Jean-Philippe Martellosio, Nathan Peiffer-Smadja, Marie Chauveau, Pierre Housset, Lionel Piroth, Mathilde Devaux, Gilles Pialoux, Aurelie Martin, Vincent Dubee, Jerome Frey, Audrey Le Bot, Charles Cazanave, Philippe Petua, Roland Liblau, Fabrice Carrat, Youri Yordanov

Summary: This study compared the clinical and virological outcomes in Omicron BA.1 and BA.2-infected patients who received sotrovimab and nirmatrelvir for the prevention of severe COVID-19. The results showed that early administration of nirmatrelvir was associated with faster viral clearance compared to sotrovimab, which may contribute to reducing transmission and preventing viral resistance.

CLINICAL MICROBIOLOGY AND INFECTION (2023)

添加到收藏夹

Letter Immunology

APOBEC-Induced Mutations at Initiation of Cabotegravir plus Rilpivirine for Two Patients Infected by HIV-1 Subtype CRF02: The Interest of Systematic Genotyping

Bruce Shinga Wembulua, Nadia Valin, Sidonie Lambert-Niclot, Estelle Nerozzi-Banfi, Thibault Chiarabini, Jean Luc Meynard, Karine Lacombe

JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2023)

添加到收藏夹

Article Infectious Diseases

Same-day initiation of bictegravir/emtricitabine/tenofovir alafenamide: Week 48 results of the FAST study-IMEA 055

Antoine Bachelard, Valentina Isernia, Charlotte Charpentier, Aida Benalycherif, Marion Mora, Cecile Donadille, Claudine Duvivier, Karine Lacombe, Mayssam El Mouhebb, Bruno Spire, Roland Landman, Diane Descamps, Gilles Peytavin, Lambert Assoumou, Jade Ghosn, FAST sty grp

Summary: Initiating same-day ART for newly HIV-diagnosed individuals reduces transmission risk and improves treatment adherence. The BIC/FTC/TAF regimen has been shown to be safe, effective, and well accepted for same-day initiation.

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2023)

添加到收藏夹

Letter Dermatology

Clinical and pathological features of cutaneous manifestations in VEXAS syndrome: A multicenter retrospective study of 59 cases

Eve Zakine, Loula Papageorgiou, Rim Bourguiba, Arsene Mekinian, Benjamin Terrier, Olivier Kosmider, Pierre Hirsch, Marie Jachiet, Sylvain Audia, Samuel Ardois, Leopold Adelaide, Adrien Bigot, Paul Duriez, Jean-Francois Emile, Estibaliz Lazaro, Damien Fayard, Joris Galland, Miguel Hie, Sebastien Humbert, Alexis Jean, Marie Kostine, Valentin Lacombe, Guillaume Le Guenno, Herve Lobbes, Nadine Magy-Bertrand, Paola Marianetti-Guingel, Alexis Mathian, Roderau Outh, Clemence Saillard, Maxime Samson, Guillaume Vial, Jean-David Bouaziz, Philippe Moguelet, Francois Chasset

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2023)

添加到收藏夹

Article Gastroenterology & Hepatology

Performance of algorithms for identifying patients with chronic hepatitis B or C infection in the french health insurance claims databases using the ANRS CO22 HEPATHER cohort

Laurent Lam, Helene Fontaine, Nathanael Lapidus, Jonathan Bellet, Clovis Lusivika-Nzinga, Jerome Nicol, Celine Dorival, Carole Cagnot, Gilles Hejblum, Stanislas Pol, Marc Bourliere, Fabrice Carrat, NRS AFEF HEPATHER Std Grp

Summary: This study evaluated the validity of algorithms for identifying patients with chronic HBV or HCV infection. The results showed that multi-criteria algorithms perform well in identifying these patients and can be used to estimate the public health burden associated with hepatitis B and C in France.

JOURNAL OF VIRAL HEPATITIS (2023)

添加到收藏夹

Article Gastroenterology & Hepatology

Hepatitis delta infection among persons living with HIV in Europe

Charles Beguelin, Andrew Atkinson, Anders Boyd, Karolin Falconer, Nikolai Kirkby, Franziska Suter-Riniker, Huldrych F. Guenthard, Juergen K. Rockstroh, Amanda Mocroft, Andri Rauch, Lars Peters, Gilles Wandeler

Summary: A study found a high prevalence of hepatitis delta virus (HDV) infection among persons living with HIV (PLWH) in Europe, which is the most severe form of viral hepatitis. This study analyzed data from a large HIV cohort collaboration to characterize the epidemiological trends of HDV in Europe and its impact on clinical outcomes.

LIVER INTERNATIONAL (2023)

添加到收藏夹

Article Public, Environmental & Occupational Health

Impact of direct-acting antiviral treatment for hepatitis C on cardiovascular diseases and extrahepatic cancers

Laurent Lam, Helene Fontaine, Nathanael Lapidus, Celine Dorival, Jonathan Bellet, Dominique Larrey, Pierre Nahon, Alpha Diallo, Carole Cagnot, Clovis Lusivika-Nzinga, Francois Teoule, Gilles Hejblum, Marc Bourliere, Stanislas Pol, Fabrice Carrat

Summary: This study examined the impact of direct-acting antivirals (DAAs) on cardiovascular events and extrahepatic cancers in patients with chronic hepatitis C (CHC). The results showed that DAAs reduced the risk of peripheral arterial disease (PAD) and had a beneficial effect on overall cardiovascular outcomes in patients with advanced fibrosis. However, there was an increased risk of arrhythmias and conduction disorders (ACD) after the first year of DAA therapy. There was no association between DAA use and extrahepatic cancer risk. Therefore, long-term cardiac monitoring is necessary after DAA therapy.

PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2023)

添加到收藏夹

Article Economics

Patient-Reported Outcomes During and After Hepatitis C Virus Direct-Acting Antiviral Treatment Among People Who Inject Drugs

Qinglu Cheng, Evan B. Cunningham, Sophy Shih, Janaki Amin, Julie Bruneau, Adelina A. Artenie, Jeff Powis, Alain H. Litwin, Curtis Cooper, Olav Dalgard, Margaret Hellard, Philip Bruggmann, Philippa Marks, Karine Lacombe, Catherine Stedman, Phillip Read, Behzad Hajarizadeh, Adrian J. Dunlop, Brian Conway, Jordan J. Feld, Gregory J. Dore, Jason Grebely

Summary: This study aimed to assess the change in patient-reported outcomes (PROs) during and after hepatitis C virus (HCV) direct-acting antiviral (DAA) treatment among people who inject drugs (PWID). The study found no significant improvement in health-related quality of life, social functioning, psychological distress, and housing, but there was a significant increase in employment. These results highlight the need for comprehensive models of HCV care for PWID to improve their quality of life.

VALUE IN HEALTH (2023)

添加到收藏夹

Article Medicine, General & Internal

Inflammatory markers and auto-Abs to type I IFNs in COVID-19 convalescent plasma cohort study

Fabrice Cognasse, Hind Hamzeh-Cognasse, Mickael Rosa, Delphine Corseaux, Brigitte Bonneaudeau, Chloe Pierre, Julie Huet, Charles Antoine Arthaud, Marie Ange Eyraud, Amelie Prier, Anne Claire Duchez, Theo Ebermeyer, Marco Heestermans, Estelle Audoux-Caire, Quentin Philippot, Tom Le Voyer, Olivier Hequet, Anne-Marie Fillet, Patricia Chavarin, Dominique Legrand, Pascale Richard, France Pirenne, Pierre Gallian, Jean Laurent Casanova, Sophie Susen, Pascal Morel, Karine Lacombe, Paul Bastard, Pierre Tiberghien

Summary: COVID-19 convalescent plasma (CCP) contains neutralising antibodies that may be useful as passive immunotherapy. CCP showed increased levels of IL-6 and TNF-alpha and lower levels of IL-10 compared to control plasma. Auto-Antibodies against type I IFNs in CCP were not associated with reported adverse events. Further studies are needed to define the clinical relevance of these findings.

EBIOMEDICINE (2023)

添加到收藏夹

Review Biochemistry & Molecular Biology

Harnessing Redox Disruption to Treat Human Herpesvirus 8 (HHV-8) Related Malignancies

Adelie Gothland, Aude Jary, Philippe Grange, Valentin Leducq, Laurianne Beauvais-Remigereau, Nicolas Dupin, Anne-Genevieve Marcelin, Vincent Calvez

Summary: Reprogrammed metabolism, redox equilibrium, and ROS production play important roles in cancer development and are particularly influential in HHV-8 related diseases such as Kaposi sarcoma and primary effusion lymphoma. Primaquine diphosphate has been found to induce apoptosis in HHV-8 infected PEL cell lines through ROS production, indicating that targeting the redox balance could be a potential approach for treating HHV-8 related diseases. This review focuses on the role of ROS in cancer development and provides evidence for the importance of redox pathways in HHV-8 pathologies.

ANTIOXIDANTS (2023)

添加到收藏夹

Review Microbiology

Epidemiology and Characteristics of SARS-CoV-2 Variants of Concern: The Impacts of the Spike Mutations

Theophile Cocherie, Karen Zafilaza, Valentin Leducq, Stephane Marot, Vincent Calvez, Anne-Genevieve Marcelin, Eve Todesco

Summary: SARS-CoV-2 variants of concern have evolved through the accumulation of mutations in the Spike protein, which is responsible for viral binding and contains immunodominant epitopes. Different variants have emerged, each with unique characteristics in terms of transmissibility, virulence, and immune escape. The appearance of successive variants has led to the progressive improvement of SARS-CoV-2's transmissibility and its ability to evade the immune system. This review provides a comprehensive summary of the impacts of Spike mutations and the variants of concern.

MICROORGANISMS (2023)

添加到收藏夹

Article Medicine, Research & Experimental

Evaluating interventions to reduce behaviour associated with HCV reinfection in men who have sex with men: study protocol for a non-blinded, phase 2, randomised trial

Kris Hage, Anders Boyd, Udi Davidovich, Paul Zantkuijl, Elske Hoornenborg, Amy Matser, Ellen Generaal, Janke Schinkel, Eve Todesco, Marc van der Valk, Hayette Rougier, Karine Lacombe, Maria Prins

Summary: The ICECREAM study aims to decrease the risk of HCV reinfection in MSM with previous HCV infection through online interventions and self-sampling tests, ultimately contributing to HCV micro-elimination.

TRIALS (2023)

添加到收藏夹

Article Medicine, General & Internal

Risk of SARS-CoV-2 Infection Among Households With Children in France, 2020-2022

Simon Galmiche, Tiffany Charmet, Arthur Rakover, Laura Schaeffer, Olivia Cheny, Cassandre von Platen, Faiza Omar, Christophe David, Alexandra Mailles, Fabrice Carrat, Arnaud Fontanet

Summary: This study aimed to understand the contribution of children to the risk of SARS-CoV-2 infection in household members. The study found that living with children, especially very young ones, was associated with an increased risk of SARS-CoV-2 infection, particularly during the Delta and Omicron BA.1 waves. These findings can help guide policies targeting children and immunocompromised members of households.

JAMA NETWORK OPEN (2023)

添加到收藏夹

Article Infectious Diseases

Prolonged replication of BA.1 and BA.2 Omicron lineages compared to Delta variant in nasopharyngeal samples from COVID-19 patients

Elisa Teyssou, Stephane Marot, Theophile Cocherie, Antoine Fauchois, Basma Abdi, Eve Todesco, Sepideh Akhavan, Valerie Pourcher, Vincent Calvez, Anne-Genevieve Marcelin, Cathia Soulie

Summary: This study aimed to characterize and compare the viral loads (VL) of the Omicron BA.1 and BA.2 lineages and the Delta variant in newly diagnosed COVID-19 patients. The results showed no significant difference in the median CT value between the Delta variant and the two Omicron lineages during the first diagnostic test. However, the kinetics of CT decreases for the BA.1 and BA.2 lineages were significantly longer than the kinetics for the Delta variant. The BA.2 lineage had a lower median CT value (inversely proportional to the VL) compared to the BA.1 lineage. In conclusion, the BA.2 Omicron lineage presented higher VL at diagnostic and both BA.1 and BA.2 lineages had more prolonged replication compared to the Delta variant.

INFECTIOUS DISEASES NOW (2023)

添加到收藏夹

暂无数据

© Peeref 2019-2024. All rights reserved.